Urogen Pharma (URGN) Stock Statistics & Valuation Metrics

Urogen Pharma has a market cap or net worth of $911.82M. The enterprise value is $929.41M.

Urogen Pharma has 48,682,280 shares outstanding. The number of shares has decreased by -2.65% in one year.

Urogen Pharma’s return on equity (ROE) is 1.46 and return on invested capital (ROIC) is -81.06%.

The current PE Ratio of Urogen Pharma is ―. Urogen Pharma’s PEG ratio is -0.94.

In the last 12 months, Urogen Pharma had revenue of 109.79M and earned -153.49M in profits. Earnings per share was -3.19.

In the last 12 months, operating cash flow was -162.44M and capital expenditures -289.00K, giving a free cash flow of -162.73M billion.

Urogen Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Urogen Pharma upcoming earnings date is May 7, 2026, Before Open (Confirmed).

Urogen Pharma as a current ratio of 4.01, with Debt / Equity ratio of -121.67%

In the past 12 months, Urogen Pharma has paid 78.00K in taxes.

Urogen Pharma EV to EBITDA ratio is -8.44, with an EV/FCF ratio of -7.03.

Urogen Pharma has $120.46M in cash and marketable securities with $128.33M in debt, giving a net cash position of -$7.88M billion.

Gross margin is 88.66%, with operating margin of -113.73%, and net profit margin of -139.81%.

The average price target for Urogen Pharma is $36.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy